BridgeBio Pharma, Inc.
NASDAQ:BBIO · NASDAQ Global Select
+$0.75 today
Vol 3.50M · Avg 2.49M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
35.1%
avg -53.8%
ROIC
-108.5%
avg -79.7%
ROA
-77.9%
avg -61.2%
Analysis
ROE is currently the strongest return metric at 35.1% versus its period average of -53.8%. 1 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Neil Kumar | Co-Founder, Chief Executive Officer & Director | $2.46M | — | 47 | $515,686.00 | 0.26% |
Uma Sinha | Chief Scientific Officer | $1.31M | — | 68 | $10,832.00 | <0.01% |
Thomas Trimarchi | Chief Financial Officer & President | $1.23M | — | 41 | $362,389.00 | 0.19% |
Charles J. Homcy | Co-Founder, Chairman of Pharmaceuticals & Independent Lead Director | $574,167.00 | — | 78 | $916,674.00 | 0.47% |
Frank McCormick | Co-Founder, Chairman of Oncology & Director | $550,000.00 | — | 76 | $735,467.00 | 0.38% |
Richard H. Scheller | Chairman of Research & Development | $509,622.00 | — | 73 | $55,126.00 | 0.03% |
Jonathan C. Fox FACC | President & Chief Medical Officer of Cardiovascular and Renal Diseases | — | — | 69 | — | — |
Matthew Outten | Chief Commercial Officer | — | — | 52 | — | — |
Maricel Apuli | Chief Accounting Officer | — | — | 49 | $129,401.00 | 0.07% |
Eric Michael David | Chief Executive Officer of Gene Therapy | — | — | 54 | $8,425.00 | <0.01% |
Eli Wallace | Chief Scientific Officer of Oncology | — | — | 59 | — | — |
Adora Ndu | Chief Regulatory Affairs Officer | — | — | 45 | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
0
$0.00
Sells
142
$96.09M
Net Sentiment
$96.09M
Net selling
Most Active
Kumar Neil
105 transactions
1–10 of 142
Analysis
Insiders reported 0 buys worth $0.00 and 142 sells worth $96.09M over the last 12 months. That adds up to net selling of $96.09M. Kumar Neil was the most active insider with 105 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A6 analysts |
| Revenue | N/A | N/A | N/A | +58.8% (9yr)8 analysts |
| Net Income | N/A | N/A | N/A | N/A8 analysts |
| EBIT | N/A | N/A | N/A | N/A8 analysts |
Analysis
Forward estimates point to Revenue at +58.8% (9yr), giving you a quick read on expected growth from here.
Competitors
Peer companies in the same sector
Revolution Medicines, Inc.
NASDAQ:RVMD
$33.54B
Moderna, Inc.
NASDAQ:MRNA
$24.52B
Roivant Sciences Ltd.
NASDAQ:ROIV
$22.44B
Ascendis Pharma A/S
NASDAQ:ASND
$14.36B
Jazz Pharmaceuticals plc
NASDAQ:JAZZ
$14.26B
Exelixis, Inc.
NASDAQ:EXEL
$13.18B
Ionis Pharmaceuticals, Inc.
NASDAQ:IONS
$12.28B
Summit Therapeutics Inc.
NASDAQ:SMMT
$10.91B
BioMarin Pharmaceutical Inc.
NASDAQ:BMRN
$10.63B
Atrium Therapeutics, Inc.
NASDAQ:RNA
$213.48M
Who manages BBIO?
BridgeBio Pharma, Inc. (BBIO) lists 12 active executives. The top listed executive is Neil Kumar, Co-Founder, Chief Executive Officer & Director.
Are BBIO insiders buying or selling?
Recent insider activity shows net selling of $108.93M.
Explore More
Continue the stock analysis
Jump to another research area for this company.